MedCram Episode 130. NB1.8.1. SARS CoV-2 Variant Spreading to US, Interferon, & HHS Cuts Funding for Moderna H5N1 Vaccine
Jun 2, 2025
A new COVID variant, NB.1.8.1, is making its way to the U.S., raising concerns due to its genetic mutations and ability to escape immunity. The podcast dives into the role of interferon in the immune response against SARS-CoV-2. It also discusses the controversial HHS funding cuts for the Moderna H5N1 vaccine and suggests alternative treatments like hydrotherapy to boost immunity. The mix of emerging threats and evolving vaccine strategies keeps the conversation timely and engaging.
AI Snips
Chapters
Transcript
Episode notes
NB.1.8.1 Variant Overview
- The NB.1.8.1 SARS-CoV-2 variant (Nimbus) is spreading in Australia and parts of Asia with increased infectiousness.
- Despite antibody escape, it does not seem to cause more severe disease compared to previous variants.
NB.1.8.1 Infectivity and Immunity
- NB.1.8.1 has higher binding affinity to ACE2 receptors, which may increase its infectivity.
- It currently shows about a 1.5-fold reduction in antibody neutralization compared to dominant strains.
Interferon's Role and Viral Evasion
- Interferon is a crucial innate immune protein that interferes with viral infections.
- Most viruses, including SARS-CoV, have evolved mechanisms to block or evade the interferon pathway.